Fumaric Acid

Fumaric Acid

SCHEMBL394440

CCCC.CCCC[Sn+2]CCCC.O=C([O-])/C=C\C(=O)[O-]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.38
CES1 P23141 6/20 0.37
CES2 O00748 5/20 0.37
ATM Q13315 1/20 0.34
BBOX1 O75936 1/20 0.34
FABP3 P05413 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL8382075 0.98 CA1 (0.39) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL621871 0.98 CA1 (0.39) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL48774 0.98 CA1 (0.39) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL3685229 0.98 CA1 (0.39) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL8378110 0.98 CA1 (0.39) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL48771 0.98 CA1 (0.39) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL28546317 0.96 CA1 (0.38) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL3629101 0.96 CA1 (0.38) CA1CES1CES2ATMBBOX1
Fumaric Acid SCHEMBL28649556 0.92 CES2 (0.41) CES1CES2FABP3
Fumaric Acid SCHEMBL28841512 0.92 CA1 (0.35) CA1CES1CES2ATMBBOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025075042-A1 TWO-PACK TYPE CURABLE COMPOSITION AND USE THEREOF 株式会社カネカ 2025-04-10 WO disclosed
US-8642669-B2 Foamable low-viscosity mixtures HENKEL AG & CO., KGAA (DE) 2014-02-04 US disclosed
US-20120260934-A1 HAIR TREATMENT AGENTS COMPRISING TRIALKOXYSILANE-SUBSTITUTED COMPOUNDS AND ALKOXYSILYL-MODIFIED MACRO MOLECULES SCHWEINSBERG MATTHIAS (DE) 2012-10-18 US disclosed
US-8101681-B2 Prepolymer mixture containing silyl groups and use thereof HENKEL AG & CO. KGAA (DE) 2012-01-24 US disclosed
EP-1586605-B1 POLYMER AND CURABLE COMPOSITIONS IMPROVED IN STORAGE STABILITY KANEKA CORP (JP) 2011-11-02 EP disclosed
US-20110224319-A1 FOAMABLE LOW-VISCOSITY MIXTURES HENKEL AG & CO. KGAA (DE) 2011-09-15 US disclosed
US-7977399-B2 Curable composition KANEKA CORPORATION (JP) 2011-07-12 US disclosed
US-7820749-B2 Curable resin composition KANEKA CORPORATION (JP) 2010-10-26 US disclosed
EP-2072577-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2010-08-04 EP disclosed
US-20100105798-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-04-29 US disclosed
US-20090306283-A1 PREPOLYMER MIXTURE CONTAINING SILYL GROUPS AND USE THEREOF HENKEL AG & CO. KGAA (DE) 2009-12-10 US disclosed
US-20090170995-A1 Curable Resin Composition KANEKA CORPORATION (JP) 2009-07-02 US disclosed
EP-2072577-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2009-06-24 EP disclosed
EP-2011833-A1 CURABLE RESIN COMPOSITION Kaneka Corporation (JP) 2009-01-07 EP disclosed
US-20070161768-A1 Method for producing hydrolyzable silicon group-containing oxyalkylene polymer and curing composition thereof KANEKA CORPORATION (JP) 2007-07-12 US disclosed
EP-1710270-A1 METHOD FOR PRODUCING HYDROLYZABLE SILICON GROUP-CONTAINING OXYALKYLENE POLYMER AND CURING COMPOSITION THEREOF Kaneka Medix Corporation (JP) 2006-10-11 EP disclosed
US-20060205887-A1 Polymer and curable compositions improved in storage stability KANEKA CORPORATION (JP) 2006-09-14 US disclosed
US-20060173121-A1 Curable composition KANEKA CORPORATION (JP) 2006-08-03 US disclosed
EP-1650261-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2006-04-26 EP disclosed
EP-1586605-A1 POLYMER AND CURABLE COMPOSITIONS IMPROVED IN STORAGE STABILITY KANEKA CORPORATION (JP) 2005-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120260934-A1 HAIR TREATMENT AGENTS COMPRISING TRIALKOXYSILANE-SUBSTITUTED COMPOUNDS AND ALKOXYSILYL-MODIFIED MACRO MOLECULES KRT18, MARK1, TLN1 CA1 3561/4885CES1 3492/4885CES2 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.